NALA
Clinical Trial Program
A study of neratinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2+ metastatic breast cancer who have received two or more prior HER2 directed regimens in the metastatic setting (NALA).
Phase III
Status
Finished
Tumour subtype:
HER2+
Scenario
Locally Advanced or Metastatic
SPONSOR
COLLABORATORS
PRINCIPAL INVESTIGATORS
Cristina Saura, MD, (Hospital Universitari de la Vall d'Hebron)
José Baselga, MD, PhD (Memorial Sloan-Kettering Cancer Center)
Sites
CENTRO ONCOLOGICO MD ANDERSON INTERNACIONAL ESPAÑA, COMPLEJO HOSPITALARIO DE JAEN, CONSORCIO HOSPITALARIO PROVINCIAL DE CASTELLON, HOSPITAL CLÍNICO UNIV. LOZANO BLESA, HOSPITAL CLÍNICO UNIV. SANTIAGO DE COMPOSTELA, HOSPITAL CLÍNICO UNIVERSITARIO DE VALENCIA, HOSPITAL SON ESPASES, HOSPITAL SON LLATZER, HOSPITAL UNIVERSITARI ARNAU DE VILANOVA DE LLEIDA, HOSPITAL UNIVERSITARI SANT JOAN DE REUS, HOSPITAL UNIVERSITARI VALL D’HEBRON, HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, HOSPITAL UNIVERSITARIO CLÍNICO SAN CARLOS, HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR. NEGRIN, HOSPITAL UNIVERSITARIO MADRID SANCHINARRO (CENTRO INTEGRAL ONCOLÓGICO CLARA CAMPAL (CIOCC)), HOSPITAL UNIVERSITARIO QUIRÓN MADRID, HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA, HOSPITAL UNIVERSITARIO VIRGEN DE LA MACARENA, HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO, HU PUERTA DE HIERRO DE MAJADAHONDA, ICO GIRONA (HOSPITAL DR. JOSEP TRUETA), HOSPITAL DA LUZ, IPO LISBOA (INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL, EPE), IPO PORTO (INSTITUTO PORTUGUÊS DE ONCOLOGIA DE PORTO FRANCISCO GENTIL, EPE )
